Monte Rosa sets RP2D for MRT-2359 at 0.5 mg/day 21/7 schedule; safety, PD data positive

Monte Rosa Therapeutics, Inc.

RP2D selected: 0.5 mg daily on 21-days-on/7-days-off schedule based on favorable safety and ~60% GSPT1 degradation.
No hypotension, cytokine release syndrome, or clinically significant hypocalcemia observed at any dose.
Doses ≥1.5 mg/day on 5/9 schedule exceeded MTD; thrombocytopenia was DLT; 0.5 and 1 mg were tolerable.
Combination safety assessments started: MRT-2359 + enzalutamide in prostate cancer and + fulvestrant in breast cancer.
Updated biomarker and activity data from Phase 1/2 study expected in Q1 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.